File a Clinical Trial Application for a Phase 1 study of UNI-494 in the UK
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Nov 2022
- Due
- 31 Dec 2022
- Delivered
- December 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company’s plan is to file a Clinical Trial Application (CTA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK... by the end of the year.”
What we found
Evidence strength A What the grades mean
The company successfully submitted the Clinical Trial Application to the UK's MHRA in December 2022, meeting its stated deadline.
-
A Unicycive Therapeutics, Inc. 10-K filed 2023-03-31
“submitted a Clinical Trial Application (CTA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1 study in healthy volunteers in the United Kingdom in December 2022.” ✓ confirmed on the page
Market reaction: the shares moved +14.7% against the S&P 500 over the three sessions around the disclosure (30 Mar 2023 to 4 Apr 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 14 Nov 2022
Deadline 31 Dec 2022 (“by the end of the year”) · wording expected
-
Version 2 · stated 13 May 2024
Deadline 31 Dec 2024 (“in the second half of this year”) · wording expected
“we expect to complete the trial and report the full results in the second half of this year.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- UNI-494 Clinical Trial Application
- Where
- UK
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-UNCY-002778 · Corrections policy